2/9/2026

Janusmed sex and gender

Janusmed sex and gender – Lumacaftor

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
C C
C C

Lumacaftor

Lumacaftor

Class : C

Show all info

Print

Contact us

  1. Assessment report - Orkambi (lumacaftor/ivacaftor). European Medicines Agency (EMA) [www]. [cited 2025-12-19].

  2. Socialstyrelsen. Sällsynta hälsotillstånd - cystisk fribros. Socialstyrelsen [www]. [updated 2022-01-21, cited 2025-12-19].

  3. Olesen HV, Pressler T, Hjelte L, Mared L, Lindblad A, Knudsen PK et al. Gender differences in the Scandinavian cystic fibrosis population. Pediatr Pulmonol. 2010;45(10):959-65.

  4. Holtrop M, Cosmich S, Lee M, Keller A, Jain R. Sex Differences After Treatment With Ivacaftor in People With Cystic Fibrosis. Chest. 2024;166(5):951-962.

  5. Harness-Brumley CL, Elliott AC, Rosenbluth DB, Raghavan D, Jain R. Gender differences in outcomes of patients with cystic fibrosis. J Womens Health (Larchmt). 2014;23(12):1012-20.

  6. Lam GY, Goodwin J, Wilcox PG, Quon BS. Sex disparities in cystic fibrosis: review on the effect of female sex hormones on lung pathophysiology and outcomes. ERJ Open Res. 2021;7(1):.

  7. Aalbers BL, Hofland RW, Bronsveld I, de Winter-de Groot KM, Arets HGM, de Kiviet AC et al. Females with cystic fibrosis have a larger decrease in sweat chloride in response to lumacaftor/ivacaftor compared to males. J Cyst Fibros. 2021;20(1):e7-e11.

  8. Jennings MT, Dezube R, Paranjape S, West NE, Hong G, Braun A et al. An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor. Ann Am Thorac Soc. 2017;14(11):1662-1666.

  9. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2024 [cited 2025-04-23.]

  1. Assessment report - Orkambi (lumacaftor/ivacaftor). European Medicines Agency (EMA) [www]. [cited 2025-12-19].
  2. Socialstyrelsen. Sällsynta hälsotillstånd - cystisk fribros. Socialstyrelsen [www]. [updated 2022-01-21, cited 2025-12-19].
  3. Olesen HV, Pressler T, Hjelte L, Mared L, Lindblad A, Knudsen PK et al. Gender differences in the Scandinavian cystic fibrosis population. Pediatr Pulmonol. 2010;45(10):959-65.
  4. Holtrop M, Cosmich S, Lee M, Keller A, Jain R. Sex Differences After Treatment With Ivacaftor in People With Cystic Fibrosis. Chest. 2024;166(5):951-962.
  5. Harness-Brumley CL, Elliott AC, Rosenbluth DB, Raghavan D, Jain R. Gender differences in outcomes of patients with cystic fibrosis. J Womens Health (Larchmt). 2014;23(12):1012-20.
  6. Lam GY, Goodwin J, Wilcox PG, Quon BS. Sex disparities in cystic fibrosis: review on the effect of female sex hormones on lung pathophysiology and outcomes. ERJ Open Res. 2021;7(1):.
  7. Aalbers BL, Hofland RW, Bronsveld I, de Winter-de Groot KM, Arets HGM, de Kiviet AC et al. Females with cystic fibrosis have a larger decrease in sweat chloride in response to lumacaftor/ivacaftor compared to males. J Cyst Fibros. 2021;20(1):e7-e11.
  8. Jennings MT, Dezube R, Paranjape S, West NE, Hong G, Braun A et al. An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor. Ann Am Thorac Soc. 2017;14(11):1662-1666.
  9. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2024 [cited 2025-04-23.]